Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"“Thirty-four percent of patients had an AS1411-related adverse event, all of which were mild or moderate” maybe they were concerned about the safety profile."

Did you leave out a link because the quote is from a 2014 cancer trial?


If the FDA was concerned about the safety profile they wouldn't have been "in general agreement with the Company's planned clinical development of AS1411, a nucleolin-targeting DNA aptamer drug candidate, for the treatment of COVID-19."